Viking Therapeutics VKTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $453.72M+281% | $344.96M+239% | $222.48M+144% | $155.32M+79.0% | $118.93M+54.7% | ||
| $48.28M-9.6% | $48.39M-1.8% | $52.36M+22.3% | $57.52M+51.7% | $53.39M+42.5% | ||
| $502M+191% | $393.34M+161% | $274.84M+105% | $212.84M+70.7% | $172.32M+50.7% | ||
| -$502M-191% | -$393.34M-161% | -$274.84M-105% | -$212.84M-70.7% | -$172.32M-50.7% | ||
| $29.64M-32.7% | $33.7M-17.7% | $37.51M+7.8% | $41.27M+47.4% | $44.06M+113% | ||
| $29.66M-32.7% | $33.7M-17.7% | $37.45M+7.6% | $41.29M+47.8% | $44.08M+114% | ||
| -$472.34M-268% | -$359.64M-227% | -$237.39M-139% | -$171.55M-77.3% | -$128.24M-36.8% | ||
| -$4.15-261% | -$3.19-219% | -$2.12-128% | -$1.53-62.8% | -$1.15-23.7% | ||
| -$502M-191% | -$393.34M-161% | -$274.84M-105% | -$212.84M-70.7% | -$172.32M-50.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's income statement data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.